Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prothena (PRTA)
NASDAQ:PRTA
Holding PRTA?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-1.02Last Year’s EPS
-1.26Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2018
|% Change Since: -20.68%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook for Prothena, with strong financial results for 2023, substantial advancements in their clinical programs, and a significant collaboration milestone with BMS. However, the increased forecasted cash burn for 2024 and the reliance on future clinical readouts present potential risks.Company Guidance
During Prothena's fourth-quarter and full-year 2023 earnings call, guidance for 2024 was provided by Tran Nguyen, the CFO and Chief Strategy Officer. The company anticipates a net cash usage in operating and investing activities between $208 million and $225 million, ending the year with approximately $405 million in cash, cash equivalents, and restricted cash. This financial outlook is primarily driven by an estimated net loss ranging from $229 million to $255 million, including a projected $51 million in non-cash share-based compensation expenses. Prothena's strong cash position of $621 million at the end of 2023, bolstered by a $55 million milestone payment from Bristol Myers Squibb, supports its strategic objectives and upcoming clinical milestones.Strong Financial Position
Prothena ended 2023 with $621 million in cash, exceeding their guidance of $600 million, and reported favorable financial results against their 2023 guidance.
Advancement of Clinical Programs
Significant progress in clinical programs including IND clearance for PRX019 and Fast Track designation for PRX123.
Successful BMS Collaboration
BMS opted into global rights for BMS-986446, resulting in a $55 million milestone payment and plans to advance to a Phase II trial.
Potential Best-in-Class Alzheimer's Treatment
PRX012 showed promising data suggesting a once-monthly subcutaneous administration could be best-in-class for Alzheimer's disease.
---
PRTA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PRTA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $17.36 | $17.23 | -0.75% |
| Aug 08, 2024 | $19.68 | $20.55 | +4.42% |
| May 08, 2024 | $23.03 | $22.00 | -4.47% |
| Feb 15, 2024 | $28.52 | $28.02 | -1.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Prothena (PRTA) report earnings?
Prothena (PRTA) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Prothena (PRTA) earnings time?
Prothena (PRTA) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PRTA EPS forecast?
PRTA EPS forecast for the fiscal quarter 2024 (Q4) is -1.02.
---